260 related articles for article (PubMed ID: 12947099)
1. The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain.
Joaquin M; Watson RJ
J Biol Chem; 2003 Nov; 278(45):44255-64. PubMed ID: 12947099
[TBL] [Abstract][Full Text] [Related]
2. B-Myb overcomes a p107-mediated cell proliferation block by interacting with an N-terminal domain of p107.
Joaquin M; Bessa M; Saville MK; Watson RJ
Oncogene; 2002 Nov; 21(52):7923-32. PubMed ID: 12439743
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator.
Bessa M; Saville MK; Watson RJ
Oncogene; 2001 Jun; 20(26):3376-86. PubMed ID: 11423988
[TBL] [Abstract][Full Text] [Related]
4. Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression.
Hashimoto Y; Kohri K; Kaneko Y; Morisaki H; Kato T; Ikeda K; Nakanishi M
J Biol Chem; 1998 Jun; 273(26):16544-50. PubMed ID: 9632724
[TBL] [Abstract][Full Text] [Related]
5. Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor.
Castaño E; Kleyner Y; Dynlacht BD
Mol Cell Biol; 1998 Sep; 18(9):5380-91. PubMed ID: 9710622
[TBL] [Abstract][Full Text] [Related]
6. The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties.
Saville MK; Watson RJ
Oncogene; 1998 Nov; 17(21):2679-89. PubMed ID: 9840932
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D- and E-dependent kinases and the p57(KIP2) inhibitor: cooperative interactions in vivo.
Gómez Lahoz E; Liegeois NJ; Zhang P; Engelman JA; Horner J; Silverman A; Burde R; Roussel MF; Sherr CJ; Elledge SJ; DePinho RA
Mol Cell Biol; 1999 Jan; 19(1):353-63. PubMed ID: 9858559
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
9. p57(Kip2) stabilizes the MyoD protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts.
Reynaud EG; Pelpel K; Guillier M; Leibovitch MP; Leibovitch SA
Mol Cell Biol; 1999 Nov; 19(11):7621-9. PubMed ID: 10523650
[TBL] [Abstract][Full Text] [Related]
10. p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.
Zhu L; Harlow E; Dynlacht BD
Genes Dev; 1995 Jul; 9(14):1740-52. PubMed ID: 7622038
[TBL] [Abstract][Full Text] [Related]
11. PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites.
Santilli G; Cervellera MN; Johnson TK; Lewis RE; Iacobelli S; Sala A
Oncogene; 2001 Dec; 20(57):8167-74. PubMed ID: 11781832
[TBL] [Abstract][Full Text] [Related]
12. p27KIP1 blocks cyclin E-dependent transactivation of cyclin A gene expression.
Zerfass-Thome K; Schulze A; Zwerschke W; Vogt B; Helin K; Bartek J; Henglein B; Jansen-Dürr P
Mol Cell Biol; 1997 Jan; 17(1):407-15. PubMed ID: 8972221
[TBL] [Abstract][Full Text] [Related]
13. Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4.
Leng X; Noble M; Adams PD; Qin J; Harper JW
Mol Cell Biol; 2002 Apr; 22(7):2242-54. PubMed ID: 11884610
[TBL] [Abstract][Full Text] [Related]
14. Role of p27(Kip1) in human intestinal cell differentiation.
Deschênes C; Vézina A; Beaulieu JF; Rivard N
Gastroenterology; 2001 Feb; 120(2):423-38. PubMed ID: 11159883
[TBL] [Abstract][Full Text] [Related]
15. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
Matsuoka S; Edwards MC; Bai C; Parker S; Zhang P; Baldini A; Harper JW; Elledge SJ
Genes Dev; 1995 Mar; 9(6):650-62. PubMed ID: 7729684
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation and activation of B-Myb by cyclin A-Cdk2.
Ziebold U; Bartsch O; Marais R; Ferrari S; Klempnauer KH
Curr Biol; 1997 Apr; 7(4):253-60. PubMed ID: 9094315
[TBL] [Abstract][Full Text] [Related]
17. The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells.
Tyagi A; Agarwal C; Agarwal R
Cell Cycle; 2002; 1(2):137-42. PubMed ID: 12429923
[TBL] [Abstract][Full Text] [Related]
18. C/EBPalpha regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice.
Timchenko NA; Wilde M; Darlington GJ
Mol Cell Biol; 1999 Apr; 19(4):2936-45. PubMed ID: 10082561
[TBL] [Abstract][Full Text] [Related]
19. The cyclin-dependent kinase inhibitor p27(Kip1) induces N-terminal proteolytic cleavage of cyclin A.
Bastians H; Townsley FM; Ruderman JV
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15374-81. PubMed ID: 9860976
[TBL] [Abstract][Full Text] [Related]
20. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity.
Woo MS; Sánchez I; Dynlacht BD
Mol Cell Biol; 1997 Jul; 17(7):3566-79. PubMed ID: 9199292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
